Ariad submits EU MAA for ponatinib and prepares to storm Europe
This article was originally published in Scrip
Executive Summary
Ariad Pharmaceuticals has submitted its marketing authorisation application to the European Medicines Agency for ponatinib for resistant or intolerant chronic myeloid leukaemia and Philadelphia-chromosome positive acute lymphoblastic leukaemia. Tim Clackson, the firm's CSO and president of R&D, explained how Ariad will makes it name in the European oncology market and why partnering is not the way to do it.
You may also be interested in...
What’s Next After 20 Years Of NICE?
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Profile: Meindert Boysen On What Companies Should Expect From NICE And The Benefits Of Hill Walking
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.
England’s NICE Future Proofs Approach To Using Data
UK HTA body NICE is looking to the future and rethinking its approach to data and how they inform its guidance.
Need a specific report? 1000+ reports available
Buy Reports